Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00057343 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma
A Phase 3 study, sponsored by Biogen.
- Terminated
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
NCT00057343 is a Phase 3 study that was terminated before completion, run by Biogen. The registered enrollment target is 400 participants.
The verdict
NCT00057343, a Phase 3 study, was terminated before completion, sponsored by Biogen.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
Study Summary
The purpose of this study is to provide treatment for patients who have relapsed NHL or refractory NHL, and to determine the effectiveness and safety of the Zevalin and Rituxan regimens or Rituxan therapy alone on your disease.
Interventions
- DRUG Zevalin (ibritumomab tiuxetan)
- DRUG Rituxan (rituximab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2003-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00057343
The ClinicalTrials.gov registry entry for NCT00057343 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Zevalin (ibritumomab tiuxetan) is the first listed.
NCT00057343 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00057343 about?
NCT00057343 is a clinical study titled "Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma". The purpose of this study is to provide treatment for patients who have relapsed NHL or refractory NHL, and to determine the effectiveness and safety of the Zevalin and Rituxan regimens or Rituxan therapy alone on your disease.
What is the current status of trial NCT00057343?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2003-03.
What interventions are being tested in trial NCT00057343?
The interventions under investigation include: Zevalin (ibritumomab tiuxetan) (DRUG), Rituxan (rituximab) (DRUG).
Who is sponsoring clinical trial NCT00057343?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.